Table 3.

Clinical responses and survival outcomes of atezolizumab plus bevacizumab vs. lenvatinib treatment groups.

Clinical Responses and Survival Outcomes	LENV Group	ATE/BEV Group	p-Value
Entire cohort, unadjusted	n = 146	n = 86
Objective response rate, %	31.5	32.6	0.704
Overall survival, months (95% CI)	12.8 (6.7–18.9)	N/A	0.357
Progression-free survival, months (95% CI)	6.0 (5.2–6.7)	5.7 (2.1–9.3)	0.738
Entire cohort, PS-matched	n = 78	n = 78
Objective response rate, %	37.2	32.0	0.501
Overall survival, month (95% CI)	19.9 (9.8–19.9)	N/A	0.897
Progression-free survival, months (95% CI)	7.3 (5.7–9.4)	5.7 (3.8–10.5)	0.391
Entire cohort, IPTW analysis	n = 136	n = 136
Objective response rate, %	32.4	31.4	0.861
Overall survival, months (95% CI)	19.9 (11.1–N/A)	N/A	0.508
Progression-free survival, months (95% CI)	6.0 (5.0–7.3)	4.3 (3.0–8.0)	0.468

Objective response rate was assessed with RECIST 1.1.